biosimilar Archives | Be Korea-savvy
Medical Research Driving Business with Over 400 Licensing Deals

Medical Research Driving Business with Over 400 Licensing Deals

SEOUL, Nov. 16 (Korea Bizwire) – Technology Licensing Offices at hospitals, universities and research labs had successfully inked 405 technology transfer deals with businesses as of October, the Ministry of Health and Welfare revealed on November 15. Technology Licensing Offices, commonly referred to as TLOs, are organizations set up as intermediaries that serve as the [...]

Samsung BioLogics Set to Start IPO Process This Week

Samsung BioLogics Set to Start IPO Process This Week

SEOUL, Aug. 8 (Korea Bizwire) – Samsung BioLogics Co., a biosimilar firm affiliated with Samsung Group, will apply for preliminary approval this week for its initial public offering (IPO), estimated at around 3 trillion won (US$2.68 billion), South Korea’s bourse said Monday.  The firm, one of the world’s largest manufacturers of biosimilar medicine, plans to [...]

Samsung Bioepis Proves Effectiveness and Safety of Its Biosimilars

Samsung Bioepis Proves Effectiveness and Safety of Its Biosimilars

SEOUL, June 9 (Korea Bizwire) – Samsung Bioepis announced the results of clinical studies on its three biosimilars on June 8, 2016, at the Annual European Congress of Rheumatology (EULAR 2016 London) which is being held in London until June 11. The three biosimilars that are currently sold in Korea and Europe include BRENZYS (Benepali in [...]

Korea’s Biosimilar Market on the Rise

Korea’s Biosimilar Market on the Rise

SEOUL, May 24 (Korea Bizwire) – Recent anticipation predicts that Korea’s biosimilar market will grow to a 150-billion-won industry by 2019.  According to the Korea Pharmaceutical Manufacturers Association (KPMA), the industry, which was valued at 80 billion won in 2013, will grow to a 150 billion won market by 2019. The government’s active policy towards biosimilars, [...]

Samsung Subsidiary Becomes Third Biosimilar Manufacturer in Korea

Samsung Subsidiary Becomes Third Biosimilar Manufacturer in Korea

SEOUL, Mar. 11 (Korea Bizwire) — Samsung Group’s pharmaceutical subsidiary Samsung Bioepis will be the third Korean company to manufacture and distribute biosimilar products. The company confirmed that its ‘SB4′ Enbrel biosimilar drug has advanced into regulatory review for manufacturing and marketing by the Ministry of Food and Drug Safety (MFDS), according to an announcement on March [...]

Coherus BioSciences to Host Earnings Conference Call on December 15

Coherus BioSciences to Host Earnings Conference Call on December 15

REDWOOD CITY, Calif., Dec. 4 (Korea Bizwire) — Coherus BioSciences, Inc. (Nasdaq:CHRS), a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it has scheduled a conference call for Monday, December 15, 2014, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its third quarter 2014 financial results and [...]